Exodus Point Capital Management, LP Adma Biologics, Inc. Transaction History

Exodus Point Capital Management, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$3.47 - $4.61 $267,009 - $354,730	76,948 Added 23.62%	402,717 $1.44 Million
Q2 2023 Aug 10, 2023	BUY	$3.12 - $4.22 $1.02 Million - $1.37 Million	325,769 New	325,769 $1.2 Million
Q4 2022 Feb 13, 2023	SELL	$2.47 - $3.88 $39,166 - $61,525	-15,857 Reduced 30.8%	35,632 $138,000
Q3 2022 Nov 10, 2022	SELL	$2.03 - $2.86 $30,671 - $43,211	-15,109 Reduced 22.69%	51,489 $125,000
Q2 2022 Aug 19, 2022	SELL	$1.43 - $2.2 $910,270 - $1.4 Million	-636,553 Reduced 90.53%	66,598 $132,000
Q1 2022 May 13, 2022	BUY	$1.28 - $1.83 $871,619 - $1.25 Million	680,953 Added 3067.63%	703,151 $1.29 Million
Q4 2021 Feb 11, 2022	SELL	$1.09 - $1.66 $13,623 - $20,748	-12,499 Reduced 36.02%	22,198 $31,000
Q3 2021 Nov 15, 2021	BUY	$1.13 - $1.65 $39,207 - $57,250	34,697 New	34,697 $39,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.07 $139,463 - $191,185	-92,360 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.67 - $2.95 $8,844 - $15,623	-5,296 Reduced 5.42%	92,360 $163,000
Q4 2020 Feb 16, 2021	BUY	$1.8 - $2.56 $175,780 - $249,999	97,656 New	97,656 $190,000
Q3 2020 Nov 16, 2020	SELL	$2.04 - $3.74 $138,822 - $254,507	-68,050 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.42 - $3.29 $85,094 - $115,686	-35,163 Reduced 34.07%	68,050 $199,000
Q1 2020 May 15, 2020	BUY	$1.5 - $4.59 $154,819 - $473,747	103,213 New	103,213 $297,000
Q2 2019 Aug 14, 2019	SELL	$3.52 - $5.24 $54,496 - $81,125	-15,482 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.61 - $4.35 $40,408 - $67,346	15,482 New	15,482 $59,000

319

185M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.